Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Hsiao
Mei-Chun
MC
Liu
Chia-Yih
CY
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D000328:Adult; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004359:Drug Therapy, Combination; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D014179:Neurotransmitter Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride
D018759:Adrenergic Uptake Inhibitors; D003511:Cyclohexanols; D000068736:Duloxetine Hydrochloride; D014179:Neurotransmitter Uptake Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D000069470:Venlafaxine Hydrochloride